Cardiovasc Drugs Ther
December 2019
Ranolazine is an anti-anginal medication that reduces the sodium-dependent calcium overload via the inhibition of the late sodium current. After its approval for the treatment of chronic angina in 2006 in the USA, ranolazine has been reported to have several pleiotropic effects on various cardiac conditions, such as atrial fibrillation, ventricular arrhythmias, diastolic and microvascular dysfunction, and pulmonary arterial hypertension. Recently, several studies reported some promising results on the potential benefits of ranolazine on glycemic control.
View Article and Find Full Text PDFTo review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). A PubMed (1966 to October 2019) and ClinicalTrials. gov search was conducted using the keywords , and .
View Article and Find Full Text PDFBackground: Patients with peripheral arterial disease (PAD) undergoing percutaneous coronary intervention (PCI) are at elevated risk of ischemic and bleeding events. However, the optimal duration of dual antiplatelet therapy (DAPT) after PCI in patients with PAD remains unclear.
Methods: A systematic literature search was performed through June 2017 using PubMed, EMBASE and Cochrane databases with the following key terms: "dual antiplatelet therapy", "P2Y12 inhibitor", "myocardial infarction", "percutaneous coronary intervention", "stent", "peripheral arterial disease", and "ankle-brachial index".
Crustacean hyperglycemic hormone (CHH) secreted from sinus glands primarily elicits hyperglycaemia in crustaceans. CHH is particularly important for energy metabolism during environmental and physiological stress as animals switch to anaerobiosis. CHH has been purified from multiple brachyuran crab species to date, but not from the cold water Tanner crab, Chionoecetes bairdi, a species found in Alaskan coastal waters.
View Article and Find Full Text PDF